Глава 4

   1. Westcott, R., “Can Miracles Happen?” British Medical Journal 325, no. 7363 (2002): 553.

   2. Everson, T. C., “Spontaneous Regression of Cancer,” Progress in Clinical Cancer (1967): 79-95.

   3. Cole, W. H., “Efforts to Explain Spontaneous Regression of Cancer,” Journal of Surgical Oncology 17, no. 3 (1981): 201-9.

   4. Challis, G. B., H. J. Stam, G. B. Challis, et al., “The Spontaneous Regression of Cancer: A Review of Cases from 1900 to 1987,” Acta Oncologica 29, no. 5 (1990): 545-50.

   5. Bodey, B., B. Bodey, Jr., S. E. Siegel, et al., “The Spontaneous Regression of Neoplasms in Mammals: Possible Mechanisms and Their Application in Immunotherapy,” In Vivo 12, no. 1 (1998): 107-22.

   6. Papac, R. J., “Spontaneous Regression of Cancer: Possible Mechanisms,” In Vivo 12, no. 6 (1998): 571-78.

   7. Van Baalen, D. C., M. J. deVries, and M. T. Gondrie, “Psycho-social Correlates of ‘Spontaneous’ Regression in Cancer,” monograph, Department of General Pathology, Medical Faculty, Erasmus University, Rotterdam, The Netherlands, 1987.

   8. Cui, Z., M. C. Willingham, M. A. Alexander-Miller, et al., “Spontaneous Regression of Advanced Cancer: Identification of a Unique Genetically Determined, Age-Dependent Trait in Mice,” Proceedings of the National Academy of Sciences of the United States of America 100 (2003): 6682-87.

   9. Hicks, A. M., G. Riedlinger, M. C. Willingham, et al., “Transferable Anticancer Innate Immunity in Spontaneous Regression/Complete Resistance Mice,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 20 (2006): 7753-58.

   10. Trapani, J. A., and M. J. Smyth, “Functional Significance of the Perforin/Granzyme Cell Death Pathway,” Nature Reviews Immunology 2 (2005): 735-47.

   11. Voskoboinik, I., and J. A. Trapani, “Addressing the Mysteries of Perforin Function,” Immunology and Cell Biology 84 (2006): 66-71.

   12. Whiteside, T., and R. B. Herberman, “Characteristics of Natural Killer Cells and Lymphocyte-Activated Killer Cells,” Immunology and Allergy Clinics of North America 10 (1990): 663-704.

   13. Head, J. F., F. Wang, R. L. Elliott, et al., “Assessment of Immunologic Competence and Host Reactivity Against Tumor Antigens in Breast Cancer Patients: Prognostic Value and Rationale of Immunotherapy Development,” Annals of the New York Academy of Sciences 690 (1993): 340-42.

   14. Levy, S. M., R. B. Herberman, M. Lippman, et al., “Immunological and Psychosocial Predictors of Disease Recurrence in Patients with Early-Stage Breast Cancer,” Behavioral Medicine 17, no. 2 (1991): 67-75.

   15. Imai, K., S. Matsuyama, S. Miyake, et al., “Natural Cytotoxic Activity of Peripheral-Blood Lymphocytes and Cancer Incidence: An 11-Year Follow-Up Study of a General Population,” Lancet 356, no. 9244 (2000): 1795-99.

   16. Schantz, S. P., B. W. Brown, E. Lira, et al., “Evidence for the Role of Natural Immunity in the Control of Metastatic Spread of Head and Neck Cancer,” Cancer Immunology, Immunotherapy 25, no. 2 (1987): 141-48.

   17. Herberman, R. B., “Immunotherapy,” in Clinical Oncology, ed. R. J. Lenhard, R. Osteen, and T. Gansler (Atlanta, GA: American Cancer Society, 2001), 215-23.

   18. MacKie, R. M., R. Reid, and B. Junor, “Fatal Melanoma Transferred in a Donated Kidney 16 Years after Melanoma Surgery,” New England Journal of Medicine 348, no. 6 (2003): 567-68.

   19. Cui, Z., “The Winding Road to the Discovery of the SR/CR Mice,” Cancer Immunity 3 (2003): 14.

   20. Koebel, C. M., Vermi, W., Swann, J. B., et al., “Adaptive Immunity Maintains Occult Cancer in an Equilibrium State,” Nature 159 (2008): 363-76.

   21. Imai, Matsuyama, Miyake, et al., “Natural Cytotoxic Activity of Peripheral-Blood Lymphocytes and Cancer Incidence.”

   22. Herberman, “Immunotherapy.”

   23. Levy, S. M., R. B. Herberman, A. M. Maluish, et al., “Prognostic Risk Assessment in Primary Breast Cancer by Behavioral and Immunological Parameters,” Health Psychology 4, no. 2 (1985): 99-113.

   24. Lutgendorf, S. K., A. K. Sood, B. Anderson, et al., “Social Support, Psychological Distress, and Natural Killer Cell Activity in Ovarian Cancer,” Journal of Clinical Oncology 23, no. 28 (2005): 7105-13.

   25. Schantz, Brown, Lira, et al., “Evidence for the Role of Natural Immunity in the Control of Metastatic Spread of Head and Neck Cancer.”

   26. Dvorak, H. F., “Tumors: Wounds That Do Not Heal: Similarities Between Tumor Stroma Generation and Wound Healing,” New England Journal of Medicine 315, no. 26 (1986): 1650-59.

   27. Balkwill, F., and A. Mantovani, “Inflammation and Cancer: Back to Virchow?” Lancet 357, no. 9255 (2001): 539-45.

   28. Peek, R. M., Jr., S. Mohla, and R. N. DuBois, “Inflammation in the Genesis and Perpetuation of Cancer: Summary and Recommendations from a National Cancer Institute-Sponsored Meeting,” Cancer Research 65, no. 19 (2005): 8583-86.

   29. Huang, M., M. Stolina, S. Sharma, et al., “Non-Small Cell Lung Cancer Cyclooxygenase-2-Dependent Regulation of Cytokine Balance in Lymphocytes and Macrophages: Up-Regulation of Interleukin 10 and Down-Regulation of Interleukin 12 Production,” Cancer Research 58, no. 6 (1998): 1208-16.

   30. Mantovani, A., B. Bottazzi, F. Colotta, et al., “The Origin and Function of Tumor-Associated Macrophages,” Immunology Today 13, no. 7 (1992): 265-70.

   31. Baxevanis, C. N., G. J. Reclos, A. D. Gritzapis, et al., “Elevated Prostaglandin E2 Production by Monocytes Is Responsible for the Depressed Levels of Natural Killer and Lymphokine-Activated Killer Cell Function in Patients with Breast Cancer,” Cancer 72, no. 2 (1993): 491-501.

   32. Marx, J., “Cancer Research: Inflammation and Cancer: The Link Grows Stronger,” Science 306 (2004): 5698-966.

   33. Wallace, J., “Nutritional and Botanical Modulation of the Inflammatory Cascade—Eicosanoids, Cyclooxygenases, and Lipoxygenases—as an Adjunct in Cancer Therapy,” Integrative Cancer Therapies 1, no. 1 (2002): 7-37.

   34. Crumley, A. B. C., D. C. McMillan, M. McKernan, et al., “Evaluation of an Inflammation-Based Prognostic Score in Patients with Inoperable Gastro-oesophageal Cancer,” British Journal of Cancer 94, no. 5 (2006): 637-41.

   35. Al Murri, A. M., J. M. S. Bartlett, P. A. Canney, et al., “Evaluation of an Inflammation-Based Prognostic Score (GPS) in Patients with Metastatic Breast Cancer,” British Journal of Cancer 94, no. 2 (2006): 227-30.

   36. Forrest, L. M., D. C. McMillan, C. S. McArdle, et al., “Comparison of an Inflammation-Based Prognostic Score (GPS) with Performance Status (ECOG) in Patients Receiving Platinum-Based Chemotherapy for Inoperable Non-Small-Cell Lung Cancer,” British Journal of Cancer 90, no. 9 (2004): 1704-6.

   37. Harris, R. E., S. Kasbari, and W. B. Farrar, “Prospective Study of Nonsteroidal Anti-inflammatory Drugs and Breast Cancer,” Oncology Reports 6, no. 1 (1999): 71-73.

   38. Nelson, J. E., and R. E. Harris, “Inverse Association of Prostate Cancer and Non-steroidal Anti-Inflammatory Drugs (NSAIDs): Results of a Case-Control Study,” Oncology Reports 7, no. 1 (2000): 169-70.

   39. Thun, M. J., “NSAID Use and Decreased Risk of Gastrointestinal Cancers,” Gastroenterology Clinics of North America 25, no. 2 (1996): 333-48.

   40. Karin, M., and F. R. Greten, “NF-kappaB: Linking Inflammation and Immunity to Cancer Development and Progression,” Nature Reviews Immunology 5, no. 10 (2005): 749-59.

   41. Marx, “Cancer Research.”

   42. Ibid.

   43. Calcagni, E., and I. Elenkov, “Stress System Activity, Innate and T Helper Cytokines, and Susceptibility to Immune-Related Diseases,” Annals of the New York Academy of Sciences 1069 (2006): 62-76.

   44. Glaser, R., “Stress-Associated Immune Dysregulation and Its Importance for Human Health: A Personal History of Psychoneuroimmunology,” Brain, Behavior, & Immunity 19, no. 1 (2005): 3-11.

   45. Beevor, A., Stalingrad: The Fateful Siege: 1942-1943 (New York: Penguin Group, 1998).

   46. Folkman, J., “Fighting Cancer by Attacking Its Blood Supply,” Scientific American , September 1996, 150-54.

   47. Folkman, J., “Tumor Angiogenesis: Therapeutic Implications,” New England Journal of Medicine 285, no. 21 (1971): 1182-86.

   48. Ibid.

   49.  “Cancer Warrior,” NOVA Online, 2001. (Accessed November 2, 2006, at

http://www.pbs.org/wgbh/nova/cancer/program.html.)

   50. O’Reilly, M. S., L. Holmgren, Y. Shing, et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,” Cell 79, no. 2 (1994): 315-28.

   51. O’Reilly, M. S., L. Holmgren, C. Chen, et al., “Angiostatin Induces and Sustains Dormancy of Human Primary Tumors in Mice,” Nature Medicine 2, no. 6 (1996): 689-92.

   52. Rose, D. P., and J. M. Connolly, “Regulation of Tumor Angiogenesis by Dietary Fatty Acids and Eicosanoids,” Nutrition and Cancer 37, no. 2 (2000): 119-27.

   53. B?liveau, R., and D. Gingras, Foods That Fight Cancer (New York: McClelland & Stewart Ltd., 2006).

   54. B?liveau, R., and D. Gingras, “Green Tea: Prevention and Treatment of Cancer by Nutraceuticals,” Lancet 364, no. 9439 (2004): 1021-22.

   55. Rose and Connolly, “Regulation of Tumor Angiogenesis by Dietary Fatty Acids and Eicosanoids.”

   56. Ziche, M., J. Jones, and P. M. Gullino, “Role of Prostaglandin E1 and Copper in Angiogenesis,” Journal of the National Cancer Institute 69, no. 2 (1982): 475-82.